Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

The New England journal of medicine·2026

Same author

Predictors of Good Visual Recovery in Patients With Spontaneously Resolved Acute CSCR - MICRoN Report Number Thirteen.

American journal of ophthalmology·2026

Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026

Same author

Comparison between thin and thick choroid eyes in central serous chorioretinopathy.

Retina (Philadelphia, Pa.)·2026

Same author

ELLIPSOID ZONE INTEGRITY AT ANGIOGRAPHIC LEAK AFTER RESOLUTION OF CENTRAL SEROUS CHORIORETINOPATHY: MICRoN Report Number Two.

Retina (Philadelphia, Pa.)·2026

Same author

Subspecies-specific haplotype signatures for customizing blanchability in groundnut (Arachis hypogaea L.) via haplotype-based breeding.

Communications biology·2026

Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026

Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026

Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026

Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026

Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026

Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Pioglitazone: side effect and safety profile.

Priya Shah¹, Sunder Mudaliar

¹Department of Medicine, University of California at San Diego, San Diego, CA 92161, USA.

Expert Opinion on Drug Safety

|February 24, 2010

Summary

This summary is machine-generated.

Pioglitazone, a thiazolidinedione (TZD) drug, effectively lowers glucose in Type 2 diabetes. While common TZD side effects exist, pioglitazone shows a favorable safety profile without increasing mortality, making it a valuable treatment option.

Related Experiment Videos

Last Updated: Jun 16, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Area of Science:

Endocrinology
Pharmacology
Cardiovascular Medicine

Background:

Thiazolidinediones (TZDs) are PPAR-gamma agonists used for Type 2 diabetes, improving insulin sensitivity and lipid metabolism.
Past TZDs like troglitazone and rosiglitazone faced safety concerns (liver damage, cardiovascular risk).
Pioglitazone, a newer TZD, has shown potential cardiovascular benefits in some studies.

Purpose of the Study:

To review the safety and side effect profile of pioglitazone.
To assess the risks and benefits of pioglitazone in Type 2 diabetes management.

Main Methods:

Literature search of PubMed from 2000 onwards.
Review of studies focusing on pioglitazone's side effects and safety.

Main Results:

Pioglitazone is associated with common TZD adverse effects: weight gain, edema, bone loss, and heart failure risk.
No increased risk of cardiovascular disease (CVD) or all-cause mortality was observed.
The overall safety profile of pioglitazone is considered favorable.

Conclusions:

Pioglitazone remains a useful treatment for insulin resistance in Type 2 diabetes.
Adverse effects are manageable and typical for the TZD class.
Further research is needed to fully elucidate pioglitazone's cardiovascular benefits.